COVID‐19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022–2024: A Test‐Negative Case–Control Study
Influenza and Other Respiratory Viruses · 2025
DOI: 10.1111/irv.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Besfort Kryeziu und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Public Health of Kosovo, Prishtina, Kosovo. Hauptthemen laut MEDLINE: Hospitalization, COVID-19, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, World Health Organization Regional Office for Europe.
Abstract (Originalsprache)
Background
Few studies have evaluated COVID‐19 vaccine effectiveness (VE) in middle‐income countries, particularly in eastern Europe. We aimed to estimate COVID‐19 VE against SARS‐CoV‐2‐confirmed hospitalizations and severe outcomes in Kosovo.
Methods
We conducted a test‐negative case–control study using data from Kosovo's severe acute respiratory infection (SARI) sentinel surveillance system from January 2022 to June 2024. We enrolled adult patients aged ≥ 18 years hospitalized with SARI. From all patients, we collected clinical data, vaccination history, and a nasopharyngeal specimen, which was tested for SARS‐CoV‐2 using RT‐PCR. SARS‐CoV‐2‐positive patients were cases; those testing negative were controls. We estimated VE overall and against severe outcomes (requiring oxygen, intensive care admission, or in‐hospital death) using logistic regression, adjusting for age, sex, and comorbidities, calculating VE as (1–adjusted odds ratio) × 100.
Results
We included 564 SARI patients; 218 (39%) tested positive for SARS‐CoV‐2. Overall, 24% of SARI patients had received at least one COVID‐19 vaccine dose in the previous 12 months. VE against SARS‐CoV‐2‐confirmed SARI hospitalization among all adults was 72% (95% CI: 30%–89%) at 14–179‐day postvaccination, and 26% (95% CI: −33%–59%) at 180–364 days. In adults ≥ 60 years, VE was 52% (95% CI:−31%–82%) at 14–179‐day postvaccination, and −36% (95% CI: −190%–36%) at 180–364 days. VE against severe outcomes was 67% (95% CI: −14%–91%) at 14–179 days, and 17% (95% CI:−111%–67%) at 180–364 days.
Conclusions
Our findings suggest that COVID‐19 vaccination in Kosovo offered substantial protection against hospitalization and severe outcomes within 6 months, though confidence intervals were wide for some subgroups. Effectiveness waned after 6 months, highlighting the need for periodic booster doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Public Health of Kosovo, Prishtina, Kosovo.
- The Mediterranean and Black Sea Programme for Intervention Epidemiology Training (MediPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
- University "Hasan Prishtina", Faculty of Medicine, Pristina, Kosovo.
- Epiconcept, Paris, France.
- World Health Organization Regional Office for Europe, Copenhagen, Denmark.
- World Health Organization Liaison Office Kosovo, Pristina, Kosovo.
ORCID-Profile: Besfort Kryeziu, Zana Kaçaniku-Deva, James Humphreys, Angela M C Rose, Mark A Katz
Förderung
- World Health Organization
- World Health Organization Regional Office for Europe
Zitieren
APA
Kryeziu, B., Cohuet, S., Kalaveshi-Osmani, A., Kaçaniku-Deva, Z., Kaçaniku-Gunga, P., Finci, I., Sanchez, M. A., Humphreys, J., Ramadani, N., Haxhiu, E., Danis, K., Rose, A. M. C., Humolli, I., & Katz, M. A. (2025). COVID‐19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022–2024: A Test‐Negative Case–Control Study. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70152
Vancouver
Kryeziu B, Cohuet S, Kalaveshi-Osmani A, Kaçaniku-Deva Z, Kaçaniku-Gunga P, Finci I, et al. COVID‐19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022–2024: A Test‐Negative Case–Control Study. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70152
BibTeX
@article{Kryeziu2025,
author = {Kryeziu, Besfort and Cohuet, Sandra and Kalaveshi-Osmani, Ariana and Kaçaniku-Deva, Zana and Kaçaniku-Gunga, Pranvera and Finci, Iris and Sanchez, Miguel Angel and Humphreys, James and Ramadani, Naser and Haxhiu, Edita and Danis, Kostas and Rose, Angela M C and Humolli, Isme and Katz, Mark A},
title = {COVID‐19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022–2024: A Test‐Negative Case–Control Study},
journal = {Influenza and Other Respiratory Viruses},
year = {2025},
doi = {10.1111/irv.70152}
}
EUVIMED